Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Alex Yang, JD, LLM, CEO of Polaryx, a company focused on developing disease-modifying small molecule therapies for rare, pediatric lysosomal storage disorders.

Alex is a biotech executive and investor with over 25 years of experience spanning law, private equity, cross-border fund formation and strategic leadership across the biopharmaceutical sector. He currently serves investment and risk committee member roles for various regional and country-focused private equity funds. Alex was formerly a managing partner at Kim & Chang and a partner at the Ernst & Young Hong Kong office leading regional financial services practice, including banking and capital markets, asset management and insurance.

Alex graduated from New York University School of Law with both Juris Doctor (JD) and Master of Laws (LLM) degrees and a bar with the State of New York and received an undergraduate degree from Binghamton University in Economics.

Tune in to learn about how Polaryx is aiming to accelerate treatment options for patients with urgent unmet needs using robust therapeutic and flexible clinical trial designs.

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.